Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAP-BTC
2023-505722-33-00Phase 2Authorised
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Apr 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, trastuzumab, gemcitabine and cisplatin in cholangiocarcinoma (CCA) and gallbladder cancer, sponsored by Institut für Klinische Krebsforschung. Primary endpoint: ORR@6. Planned start Apr 2024; status: authorised.
02
Drugs
03
Conditions
cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on 2023-505722-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505722-33-00.